Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates

SIMPLE SUMMARY: Skeletal muscle depletion is one of the established prognostic factors for hepatocellular carcinoma (HCC). This study clearly demonstrated that skeletal muscle mass continued to decrease significantly during lenvatinib (LEN) or sorafenib (SOR) treatment, which has recently played a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Imai, Kenji, Takai, Koji, Unome, Shinji, Miwa, Takao, Hanai, Tatsunori, Suetsugu, Atsushi, Shimizu, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486953/
https://www.ncbi.nlm.nih.gov/pubmed/37686497
http://dx.doi.org/10.3390/cancers15174223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486953/
https://www.ncbi.nlm.nih.gov/pubmed/37686497
http://dx.doi.org/10.3390/cancers15174223

Ejemplares similares